Jump to content

Semantic search

 Outcome nameOutcome specification
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597OS (Overall Survival)
Toxicity
Selenium level
DFS (Disease-Free Survival)
5-year OS
NA
NA
DFS Randomization until secondary tumors or recurrence and 5-year DFS
Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck CancerSelenium level
Mucositis
NA
Inflammation of the oral mucosa (mucositis) due to radiotherapy
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neckMucositis
Tumor response
PFS (Progression-Free Survival)
OS (Overall Survival)
Quality of life
Toxicity
Grade 3 or 4
Complete response rate (CR)
NA
NA
Measured with EORTC C-30 Version 3 and EORTC QLQ - H&N35
Other treatment-associated side effects such as xerostomia, renal impairment, hearing dysfunction, and myelosuppression
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncologySelenium level
Toxicity
Performance Status
Quality of life
DFS (Disease-Free Survival)
OS (Overall Survival)
Efficiancy of supplementation
Diarrhea
NA
NA
NA
NA
Muecke et al. (2013): Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology-a subgroup analysis of a multicenter, phase III trialToxicityDiarrhea